Samsung Biologics, the biotech arm of Samsung Group, said Monday that it will participate in DCAT Week 2025, taking place March 17-20 in New York, as part of its efforts to expand its global business network.

Organized annually by the Drug, Chemical & Associated Technologies Association, the event has a history of over 130 years and is a premier networking platform for the global pharmaceutical and biotech industries.

Samsung Biologics has participated in DCAT Week every year since 2016, except in 2020, when the event was canceled due to COVID-19. This year, the company will host over 50 business meetings with global pharmaceutical firms at its dedicated meeting space.

CEO John Rim will attend for the third consecutive year, engaging with industry leaders to expand strategic partnerships and highlight Samsung Biologics' competitive strengths. The company aims to accelerate its global expansion by securing new contracts and attracting potential clients.

Additionally, on March 20, Samsung Biologics will sponsor DCAT Week’s main gala dinner, alongside major contract manufacturing firms Lonza and Thermo Fisher Scientific, providing networking opportunities with over 2,500 industry executives.

The company also plans to attend the Festival of Biologics USA in April and the PEGS Boston Summit in May to further strengthen its global business network.

By Chung Hye-lim (hyelimchung@heraldcorp.com)